Overview
This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .
Eligibility
Inclusion Criteria:
- New Diagnosed advanced myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant is planned
- Recipient of an allogeneic hematopoietic stem cell transplantation
- Age < 65 years
- ECOG performance status 2
- Written informed consent
- No psychological, familial, social, or geographic reason that would compromise clinical follow up
Exclusion Criteria:
- Relapsed or refractory advanced MDS
- Severe pshyciatric or organic disorder, supposed to be independent from advanced MDS, that would contraindicate treatment
- Known allergic or hypersensitivity to azacitidine, aclarubicin or cytarabine or to any of the test compounds, materials
- Concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the subject at unacceptable risk
- A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications